Laura Llaó-Cid

Laura Llaó-Cid

Auto-generated profile, based on publicly available information

Laura Llaó-Cid

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
FHFranziska Haderk
Franziska Haderk
RSRalph Schulz
Ralph Schulz
MIMurat Iskar
Murat Iskar
LCLaura Llaó Cid
Laura Llaó Cid
TWThomas Stefan Worst
Thomas Stefan Worst
MSMartina Seiffert
Martina Seiffert
Transfer of exosomal RNA from leukemic cells to monocytes induces immunosuppression.

20 February 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
TRTobias Roider
Tobias Roider
MBMarc-Andrea Baertsch
Marc-Andrea Baertsch
DFDonnacha Fitzgerald
Donnacha Fitzgerald
HVHarald Vöhringer
Harald Vöhringer
BBBerit J. Brinkmann
Berit J. Brinkmann
SDSascha Dietrich
Sascha Dietrich
The redirection of T cells has emerged as an attractive therapeutic principle in B cell non-Hodgkin lymphoma (B-NHL). However, a detailed characterization of lymphoma-infiltrating T cells across B-NHL entities is missing. Here we present an in-depth T cell reference map of nodal B-NHL, based on cellular indexing of transcriptomes and epitopes, T cell receptor sequencing, flow cytometry and multiplexed immunofluorescence applied to 101 lymph nodes from patients with diffuse large B cell, mantle cell, follicular or marginal zone lymphoma, and from healthy controls. This multimodal resource revealed quantitative and spatial aberrations of the T cell microenvironment across and within B-NHL entities. Quantitative differences in PD1+TCF7− cytotoxic T cells, T follicular helper cells or IKZF3+ regulatory T cells were linked to their clonal expansion. The abundance of PD1+TCF7− cytotoxic T cells was associated with poor survival. Our study portrays lymphoma-infiltrating T cells with unprecedented comprehensiveness and provides a unique resource for the investigation of lymphoma biology and prognosis.

7 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LLL. Llaó-Cid
L. Llaó-Cid
JWJkl Wong
Jkl Wong
IBI. Fernandez Botana
I. Fernandez Botana
YPY. Paul
Y. Paul
MWM. Wierz
M. Wierz
MSMartina Seiffert
Martina Seiffert
T-cell exhaustion contributes to immunotherapy failure in chronic lymphocytic leukemia (CLL). Here, we analyze T cells from CLL patients’ blood, bone marrow, and lymph nodes, as well as from a CLL mouse model, using single-cell RNA sequencing, mass cytometry, and tissue imaging. T cells in CLL lymph nodes show the most distinct profiles, with accumulation of regulatory T cells and CD8+ T cells in various exhaustion states, including precursor (TPEX) and terminally exhausted (TEX) cells. Integration of T-cell receptor sequencing data and use of the predicTCR classifier suggest an enrichment of CLL-reactive T cells in lymph nodes. Interactome studies reveal potential immunotherapy targets, notably galectin-9, a TIM3 ligand. Inhibiting galectin-9 in mice reduces disease progression and TIM3+ T cells. Galectin-9 expression also correlates with worse survival in CLL and other cancers, suggesting its role in immune evasion and potential as a therapeutic target.

22 May 2025 in Blood
Verified
Journal Article
Closed access
VCVicente Chapaprieta
Vicente Chapaprieta
AMAlba Maiques-Diaz
Alba Maiques-Diaz
FNFerran Nadeu
Ferran Nadeu
GCGuillem Clot
Guillem Clot
RMRamon Massoni-Badosa
Ramon Massoni-Badosa
JMJose I. Martin-Subero
Jose I. Martin-Subero
Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern compared with normal B cells. Here, we explored whether the level of chromatin activation is related to the clinical behavior of CLL. We identified that, in some regulatory regions, increased de novo chromatin activation is linked to clinical progression, whereas, in other regions, it is associated with an indolent course. We next developed 2 prognostic scores for progressive and indolent disease, respectively, calculated a single score representing the balance between them, and further generated surrogate scores based on gene and protein expression of the target genes. The balance score outperformed the clinical impact of the 2 individual scores, because it seemed to capture the prognostic information provided by each of them. Biologically, CLLs with higher balance score showed increased activation of tumor necrosis factor alpha (TNF-α)/NF-κB and mTOR signaling pathways. Regulatory programs related to progression were predominantly activated in the lymph node microenvironment, whereas those linked to indolent disease appeared to be microenvironment independent. Finally, we thoroughly validated the balance score as a powerful and independent quantitative prognostic factor for time to first treatment across independent CLL cohorts and data modalities, such as chromatin, transcriptome, or proteome data. Our findings support the concept that de novo acquisition of chromatin changes in CLL cells plays a dual biological role, and the balance between proprogression and proindolence is a strong independent determinant of CLL prognosis.

26 June 2025 in FEBS Letters
Verified
Journal Article
Open access
LLLaura Llaó‐Cid
Laura Llaó‐Cid
The intricate interplay between T cells and tumor cells in B‐cell malignancies has garnered significant attention in recent years. Single‐cell technologies have revolutionized our understanding of this dynamic relationship, offering unprecedented resolution and insights into cellular heterogeneity, signaling pathways, and immune interactions. This review synthesizes the recent findings that single‐cell methodologies have elucidated on the roles of T cells in the pathogenesis, progression, and therapeutic response of B‐cell malignancies. Key discoveries include the identification of previously unknown T‐cell subsets and their functional states, as well as the mechanisms of immune evasion by malignant B cells. These insights pave the way for innovative therapeutic strategies aimed at harnessing the immune system to combat B‐cell lymphomas.

1 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SLSara López-Tamargo
Sara López-Tamargo
JFJavier Fernández-Mateos
Javier Fernández-Mateos
PBPablo Bousquets-Muñoz
Pablo Bousquets-Muñoz
LLLaura Llaó-Cid
Laura Llaó-Cid
FNFerran Nadeu
Ferran Nadeu
XPXose S Puente
Xose S Puente
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal mature B lymphocytes in peripheral blood, bone marrow, lymphoid tissues, and extranodal sites. Genes involved in RNA splicing such as SF3B1 and U1 are frequently mutated in CLL, leading to altered splicing and generation of tumor neoepitopes. To study the impact of these mutations on the tumor microenvironment (TME), we have developed a comprehensive single-cell atlas of unmutated CLL encompassing 26 bone marrow and lymph node tumor samples from 23 U-CLL patients with mutations in U1 (n=7), SF3B1 (n=8), or without mutations in splicing genes (n=10). We observed high intra-tumor heterogeneity, discerning 12 transcriptional programs, one linked to the U1 g.A3>C mutation and characterized by NFKB hyperactivation. T cell and NK compartments exhibited site- and mutation-specific enrichment, with increased CD4 + regulatory cells (Treg) and CD8 + exhausted cells in lymph nodes, while U1 -mutant tumors showed increased CD8 + cytotoxic activity, with a predominance of effector-like CD8 + cells. Single-cell T cell receptor sequencing revealed clonotype expansion in U1 -mutated tumors, particularly in CD8 + effector and exhausted cells, suggesting a neoantigen-driven immune response. Cell-to-cell interaction analysis identified CD44 as a key mediator in U1 -mutated tumors, showing pro-B survival interactions as those involving MIF-CD44-CD74. Furthermore, interactions between CD80 on CLL cells and CTLA4 on Tregs and CD8 + exhausted were upregulated, reflecting an immunosuppressive phenotype associated with U1 mutated CLL. These findings highlight the complex interplay between mutations in CLL and the TME, offering novel avenues for alternative therapeutic strategies for U-CLL with mutations in U1 .